Pharmacokinetic study of the structural components of adenosine diphosphate-encapsulated liposomes coated with fibrinogen g-chain dodecapeptide as a synthetic platelet substitutes

Drug Metabolism and Disposition

Volumn 41, Issue 8, 2013, Pages 1584-1591

  Taguchi, Kazuaki ^a   Ujihira, Hayato ^a   Ogaki, Shigeru ^a   Watanabe, Hiroshi ^a,b   Fujiyama, Atsushi ^c   Doi, Mami ^c   Okamura, Yosuke ^d   Takeoka, Shinji ^c   Ikeda, Yasuo ^c   Handa, Makoto ^e   Otagiri, Masaki ^a,f   Maruyama, Toru ^a,b  

^a Graduate School of Pharmaceutical Sciences   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c WASEDA UNIVERSITY   (Japan)

^d TOKAI UNIVERSITY   (Japan)

^e KEIO UNIVERSITY   (Japan)

^f SOJO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLANTOIN; BLOOD SUBSTITUTE; CARBON 14; CHOLESTEROL; HISTIDYLHISTIDYLLEUCYLGLYCYLGLYCYLALANYLLYSYLGLUTAMINYLALANYLGLYCYLASPARTYLVALINE ADENOSINE DIPHOSPHATE LIPOSOME; PEPTIDE DERIVATIVE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RETENTION; ENCAPSULATION; LIVER; MALE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RABBIT; RAT; SINGLE DRUG DOSE; SPLEEN;

ADENOSINE DIPHOSPHATE; ANIMALS; BLOOD SUBSTITUTES; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOGEN; HUMANS; LIPOSOMES; MALE; MICE; OLIGOPEPTIDES; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84880682774     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.050005     Document Type: Article

References (37)

1. Agam G and Livne AA (1992) Erythrocytes with covalently bound fibrinogen as a cellular replacement for the treatment of thrombocytopenia. Eur J Clin Invest 22:105-112.
2. Andrieux A, Hudry-Clergeon G, Ryckewaert JJ, Chapel A, Ginsberg MH, Plow EF, and Marguerie G (1989) Amino acid sequences in fibrinogen mediating its interaction with its platelet receptor, GPIIbIIIa. J Biol Chem 264:9258-9265.
3. Blajchman MA (2003) Substitutes and alternatives to platelet transfusions in thrombocytopenic patients. J Thromb Haemost 1:1637-1641.
4. Boxenbaum H (1984) Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 15:1071-1121.
5. Casals E, Verdaguer A, Tonda R, Galán A, Escolar G, and Estelrich J (2003) Atomic force microscopy of liposomes bearing fibrinogen. Bioconjug Chem 14:593-600.
6. Coller BS, Springer KT, Beer JH, Mohandas N, Scudder LE, Norton KJ, and West SM (1992) Thromboerythrocytes. In vitro studies of a potential autologous, semi-Artificial alternative to platelet transfusions. J Clin Invest 89:546-555.
7. Coulson R (1976) Metabolism and excretion of exogenous adenosine 39:59-monophosphate and guanosine 39:59-monophosphate. Studies in the isolated perfused rat kidney and in the intact rat. J Biol Chem 251:4958-4967.
8. Dijkstra J, van Galen M, Regts D, and Scherphof G (1985) Uptake and processing of liposomal phospholipids by Kupffer cells in vitro. Eur J Biochem 148:391-397.
9. Friedman M and Byers SO (1947) Clearance of allantoin in the rat and dog as a measure of glomerular filtration rates. Am J Physiol 151:192-197.
10. George SK, Dipu MT, Mehra UR, Singh P, Verma AK, and Ramgaokar JS (2006) Improved HPLC method for the simultaneous determination of allantoin, uric acid and creatinine in cattle urine. J Chromatogr B Analyt Technol Biomed Life Sci 832:134-137.
11. Graham SS, Gonchoroff NJ, and Miller JL (2001) Infusible platelet membranes retain partial functionality of the platelet GPIb/IX/V receptor complex. Am J Clin Pathol 115:144-147.
12. Hawiger J, Kloczewiak M, Bednarek MA, and Timmons S (1989) Platelet receptor recognition domains on the alpha chain of human fibrinogen: structure-function analysis. Biochemistry 28: 2909-2914.
13. Heptinstall S, Johnson A, Glenn JR, and White AE (2005) Adenine nucleotide metabolism in human blood-important roles for leukocytes and erythrocytes. J Thromb Haemost 3:2331-2339.
14. Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, and Sugiyama Y (1996) Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 277:1630-1641.
15. Kiwada H, Matsuo H, and Harashima H (1998) Identification of proteins mediating clearance of liposomes using a liver perfusion system. Adv Drug Deliv Rev 32:61-79.
16. Kloczewiak M, Timmons S, and Hawiger J (1982) Localization of a site interacting with human platelet receptor on carboxy-terminal segment of human fibrinogen gamma chain. Biochem Biophys Res Commun 107:181-187.
17. Kloczewiak M, Timmons S, Lukas TJ, and Hawiger J (1984) Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain. Biochemistry 23:1767-1774.
18. Kuipers F, Spanjer HH, Havinga R, Scherphof GL, and Vonk RJ (1986) Lipoproteins and liposomes as in vivo cholesterol vehicles in the rat: preferential use of cholesterol carried by small unilamellar liposomes for the formation of muricholic acids. Biochim Biophys Acta 876:559-566.
19. Lam SC, Plow EF, Smith MA, Andrieux A, Ryckwaert JJ, Marguerie G, and Ginsberg MH (1987) Evidence that arginyl-glycyl-Aspartate peptides and fibrinogen gamma chain peptides share a common binding site on platelets. J Biol Chem 262:947-950.
20. Levi M, Friederich PW, Middleton S, de Groot PG, Wu YP, Harris R, Biemond BJ, Heijnen HF, Levin J, and ten Cate JW (1999) Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nat Med 5:107-111.
21. Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, Birch K, Glazer S, and Roberts HR (1994) Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 55:638-648.
22. Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Pinsky DJ, Sesti C, and Levi R (2003) Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: implications for ischemic vascular diseases. J Pharmacol Exp Ther 305:9-16.
23. Nishikawa K, Hagisawa K, Kinoshita M, Shono S, Katsuno S, Doi M, Yanagawa R, Suzuki H, Iwaya K, and Saitoh D, et al. (2012) Fibrinogen g-chain peptide-coated, ADP-encapsulated liposomes rescue thrombocytopenic rabbits from non-compressible liver hemorrhage. J Thromb Haemost 10:2137-2148.
24. Okamura Y, Eto K, Maruyama H, Handa M, Ikeda Y, and Takeoka S (2010a) Visualization of liposomes carrying fibrinogen gamma-chain dodecapeptide accumulated to sites of vascular injury using computed tomography. Nanomedicine 6:391-396.
25. Okamura Y, Katsuno S, Suzuki H, Maruyama H, Handa M, Ikeda Y, and Takeoka S (2010b) Release abilities of adenosine diphosphate from phospholipid vesicles with different membrane properties and their hemostatic effects as a platelet substitute. J Control Release 148:373-379.
26. Okamura Y, Maekawa I, Teramura Y, Maruyama H, Handa M, Ikeda Y, and Takeoka S (2005) Hemostatic effects of phospholipid vesicles carrying fibrinogen gamma chain dodecapeptide in vitro and in vivo. Bioconjug Chem 16:1589-1596.
27. Okamura Y, Takeoka S, Eto K, Maekawa I, Fujie T, Maruyama H, Ikeda Y, and Handa M (2009) Development of fibrinogen gamma-chain peptide-coated, adenosine diphosphate-encapsulated liposomes as a synthetic platelet substitute. J Thromb Haemost 7:470-477.
28. Phillips DR, Charo IF, and Scarborough RM (1991) GPIIb-IIIa: the responsive integrin. Cell 65: 359-362.
29. Rybak ME and Renzulli LA (1993) A liposome based platelet substitute, the plateletsome, with hemostatic efficacy. Biomater Artif Cells Immobilization Biotechnol 21:101-118.
30. Sakai H, Horinouchi H, Tomiyama K, Ikeda E, Takeoka S, Kobayashi K, and Tsuchida E (2001) Hemoglobin-vesicles as oxygen carriers: influence on phagocytic activity and histopathological changes in reticuloendothelial system. Am J Pathol 159:1079-1088.
31. Sakai H, Masada Y, Horinouchi H, Ikeda E, Sou K, Takeoka S, Suematsu M, Takaori M, Kobayashi K, and Tsuchida E (2004) Physiological capacity of the reticuloendothelial system for the degradation of hemoglobin vesicles (artificial oxygen carriers) after massive intravenous doses by daily repeated infusions for 14 days. J Pharmacol Exp Ther 311:874-884.
32. Taguchi K, Urata Y, Anraku M, Maruyama T, Watanabe H, Sakai H, Horinouchi H, Kobayashi K, Tsuchida E, and Kai T, et al. (2009) Pharmacokinetic study of enclosed hemoglobin and outer lipid component after the administration of hemoglobin vesicles as an artificial oxygen carrier. Drug Metab Dispos 37:1456-1463.
33. Takagi J, Petre BM, Walz T, and Springer TA (2002) Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell 110:599-611.
34. Takeoka S, Teramura Y, Okamura Y, Handa M, Ikeda Y, and Tsuchida E (2001) Fibrinogenconjugated albumin polymers and their interaction with platelets under flow conditions. Biomacromolecules 2:1192-1197.
35. Verkade HJ, Derksen JT, Gerding A, Scherphof GL, Vonk RJ, and Kuipers F (1991) Differential hepatic processing and biliary secretion of head-group and acyl chains of liposomal phosphatidylcholines. Biochem J 275:139-144.
36. Xiao T, Takagi J, Coller BS, Wang JH, and Springer TA (2004) Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 432:59-67.
37. Yamakawa N, Suemasu S, Watanabe H, Tahara K, Tanaka KI, Okamoto Y, Ohtsuka M, Maruyama T, and Mizushima T (2013) Comparison of pharmacokinetics between loxoprofen and its derivative with lower ulcerogenic activity, fluoro-loxoprofen. Drug Metab Pharmacokinet 28:118-124.